Tip-Top Treatment For Baby Bottoms


Tip-Top Treatment For Infant Bottoms

Up until just recently, mothers have had to depend on adult over the counter antifungal creams to treat their infants’ cases of diaper rash made complex by yeast infections. For the very first time, a prescription product-Vusion™ ™ (0.25%miconazole nitrate, 15% zinc oxide and 81.35% white petrolatum) Ointment-is available and is indicated and specifically formulated for the treatment of this condition, called diaper dermatitis made complex by candidiasis (DDCC), in infants 4 weeks and older. Confirmation of DDCC is identified by tiny assessment for existence of pseudohyphae or budding yeast.

DDCC is an extremely common rash in babies that can trigger great discomfort and distress. Generally, DDCC infections are identified by a rash of intense red spots with irregular, raised borders and white scales on the surface. The main spots are frequently surrounded by smaller sized patches and agonizing sores or blisters.

Babies typically get DDCC when their diapers chafe and break the surface of the skin, making it much easier for microorganisms such as yeast to get into the skin. Other risk elements for DDCC consist of diarrhea, extended diaper rash, skin hygiene and the recent use of broad-spectrum prescription antibiotics. The condition can occur anytime of year, however DDCC is frequently activated in the winter months when making use of antibiotics frequently prescribed for health problems such as ear infections is at its peak.

Treatment options have actually consisted of using antifungal products, steroids and mix items that are not particularly authorized for the treatment of DDCC or for usage on babies.

“™ With Vusion ™ Lotion now approved for the United States market, pediatricians and skin specialists can recommend a treatment specifically suggested for the condition that it was designed for which is well tolerated for use on babies,” stated Dr. Mary Spraker, a pediatric dermatologist and associate teacher in Emory University’s Department of Dermatology, who helped in the style of a Phase 3 clinical trial of the item. “Physicians are not reliant on prescribing antifungal agents planned for adults that have actually not been checked on children with DDCC.”

Vusion ™ Lotion was developed by Barrier Therapeutics, a Princeton, N.J.-based pharmaceutical business focused on the discovery, advancement and commercialization of products in the field of dermatology.